Alibaba
BABA
Broadcom
AVGO
Meta Platforms
META
4
Alphabet-C
GOOG
5
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
SHPMY SHANGHAI PHARMACEU
- 7.845
- +0.045+0.58%
15min DelayClose Jan 24 16:00 ET
5.82BMarket Cap10.59P/E (TTM)
7.845High7.845Low288Volume7.845Open7.800Pre Close2.26KTurnover0.00%Turnover Ratio11.21P/E (Static)741.59MShares9.43552wk High0.60P/B5.82BFloat Cap5.90652wk Low0.35Dividend TTM741.59MShs Float11.922Historical High4.42%Div YieldTTM0.00%Amplitude5.262Historical Low7.845Avg Price1Lot Size
SHANGHAI PHARMACEU News
[Brokerage Focus] HAITONG INT'L maintains SH PHARMA (02607) outperform rating, expects a 6.5% year-on-year revenue growth for the full year 2024.
Shanghai Pharmaceutical (2607.HK) 2024 performance forecast: pharmaceutical business grows steadily; cost reduction and efficiency continue to advance
Shanghai Pharmaceutical (601607): Integrated development of leading industries and businesses in national pharmaceutical distribution
Research Reports Gold Digger丨CICC: Maintain SH PHARMA "Outperform Industry" rating Target Price 23.3 yuan.
Shanghai Pharmaceutical (601607): The acquisition of new digestive tract products, which are expected to enrich the traditional Chinese medicine matrix, was approved for listing
Shanghai Pharmaceutical (601607): Plans to take control of Shanghai Hehuang Pharmaceutical's traditional Chinese medicine sector to further strengthen
Major Investment Ratings丨Morgan Stanley: Lowers SH PHARMA's Target Price to 17 HKD due to weak sales in the third fiscal quarter and adjusts earnings forecast.
Research report to seize opportunities | Orient Securities: sh pharma's revenue maintains steady growth, initiating a "buy" rating.
Shanghai Pharmaceutical (601607): Leading innovation, reform and revitalization in industrial and commercial integration
Citigroup: Maintains a "buy" rating on Sh Pharma (02607) with a target price lowered to 15.3 Hong Kong dollars
Major rating | Citigroup: Downgrade Shanghai Pharmaceuticals' target price to HK$15.3, maintain a "buy" rating.
Shanghai Pharmaceutical (601607) 2024 Q3 Report Review: Steady Business Growth in Q3, Improved Industrial Profitability
Soochow Securities: First buy rating given to Sh Pharma, commercial sector expected to maintain double-digit growth.
Shanghai Pharmaceutical (601607): Pharmaceutical CSO enables rapid commercial growth, and the industrial sector continues to promote research and development of new drugs
Goldman Sachs: Downgrade sh pharma's target price to HKD 12.87, lowering earnings forecast reflects lower gross margin in the third quarter.
Large-scale rating | Lyon: Raised sh pharma's target price to HK$13.8, rated "outperform".
Shanghai Pharmaceutical (601607): Steady increase in Q3 revenue side, industrial and commercial innovation continues to advance
Shanghai Pharmaceutical (601607): CSO increased 176% year over year to build an open source innovation ecosystem
Research reports Mining | Xiangcai Securities: sh pharma's overall net margin remains stable, first issued a "shareholding" rating
Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now